Genzyme and Alnylam expand collaboration on rare genetic diseases
13 January 2014 | By Sanofi
Genzyme will have significant rights to Alnylam’s portfolio of clinical and pre-clinical stage drug candidates...
List view / Grid view
News
US FDA approves FARXIGA™ (dapagliflozin) tablets for the treatment of adult patients with type 2 diabetes
13 January 2014 | By AstraZeneca
AstraZeneca and Bristol-Myers Squibb Company announced the FDA approved FARXIGA™ (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus...
Hervé Hoppenot, President of Novartis Oncology, leaves Novartis to pursue career opportunity outside of organization
12 January 2014 | By Novartis
Novartis announced that Hervé Hoppenot, President of Novartis Oncology, will leave Novartis with immediate effect...
Thomas Broeer elected as new BGMA Chair
The British Generic Manufacturers Association (BGMA) has appointed Thomas Broeer, managing director of Kent Pharmaceuticals, as its new chair for the next two years.
Biogen Idec and Sangamo BioSciences announce global collaboration to develop treatments for Hemoglobinopathies
9 January 2014 | By Biogen Idec
“Our collaboration with Sangamo is expected to help us expand our capabilities to develop treatments for people with serious, inherited hematologic conditions..."
Teva names Erez Vigodman as President and CEO
9 January 2014 | By Teva
“I would like to welcome Erez to his new position as the CEO of Teva..."
Allergan’s BOTOX® (botulinum toxin type A) receives national marketing authorisation for treatment of moderate to severe crow’s feet lines in adult patients
9 January 2014 | By Allergan
New aesthetic indication for market-leading neuromodulator which can now help improve appearance of lines around the eyes, as well as treating glabellar frown lines...
Daiichi Sankyo submits SAVAYSA(TM) (edoxaban) tablets New Drug Application to the U.S. FDA
9 January 2014 | By Daiichi Sankyo
Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism...
Daiichi Sankyo, Virtici and Celdara Medical announce collaboration to identify and progress high potential therapeutics
8 January 2014 | By Daiichi Sankyo
Virtici and Celdara Medical are affiliated, independent companies that build and develop pipelines of high potential therapeutic assets...
Merck receives FDA approval for ISENTRESS® (raltegravir) for pediatric oral suspension
8 January 2014 | By Merck
ISENTRESS is now indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in patients four weeks of age and older...
Daclatasvir marketing authorization application for treatment of chronic hepatitis C validated for accelerated regulatory review by the European Medicines Agency
8 January 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb application supports use of daclatasvir in combination with other agents for treating HCV patients with genotypes 1, 2, 3 and 4...
MedImmune and Immunocore enter immunotherapy agreement to develop novel cancer therapies
8 January 2014 | By AstraZeneca
Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology...
Quanta Fluid Solutions Ltd – Appointment of new Chief Executive Officer
8 January 2014 | By Quanta Fluid Solutions Ltd
Quanta Fluid Solutions Ltd announces the appointment of John E. Milad as Chief Executive Officer...
Daiichi Sankyo submits edoxaban Marketing Authorisation Application to the EMA for once-daily use for stroke prevention in atrial fibrillation and for the treatment and prevention of recurrence of venous thromboembolism
8 January 2014 | By Daiichi Sankyo
Daiichi Sankyo is seeking approval for edoxaban for the prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation...
Independent data monitoring committee recommends early stopping of Phase 3 study of Ibrutinib
7 January 2014 | By Johnson & Johnson
Janssen Research & Development, LLC today announced the early stopping of PCYC-1112-CA, the Phase 3 study of IMBRUVICA™ (ibrutinib) in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), based on the recommendation of an Independent Data Monitoring Committee (IDMC), which concluded that the study showed a significant…
